Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.

Endocrinol Metab (Seoul) · 2025 · PMC12765867 · PMID 41088952

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, the 10 mg group demonstrated a significant improvement in glycemic control (6.6%±1.0% to 5.9%±0.8%, P <0.01; ΔHbA1c: −0.7%±0.3%), while the reduction in body weight (91.4±11.1 kg to 85.4±11.6 kg, P =0.07; ΔBW: −6.6±5.4 kg) did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.